|
rs121913529
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs121913240
|
|
|
0.710 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs121913527
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs770248150
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs8720
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma</span> (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
|
rs7960917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
|
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer.
|
30568222 |
2019 |
|
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
|
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
|
rs121913238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Biallelic mutations in MUTYH gene were detected in 3/12 (25%) remaining subjects with polyposis and in 6/90 (6.7%) patients with colorectal cancer (CRC) carrying KRAS p.G12C substitution, but not in 231 early-onset CRC cases negative for KRAS p.G12C allele.
|
29406563 |
2018 |
|
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Comparison of the data from patients with control group showed that polymorphism of rs712 in <i>KRAS</i> gene was protective factor, which was associated with susceptibility for CRC.
|
31156795 |
2019 |
|
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03).
|
15294875 |
2004 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
|
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |
|
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In conclusion, minor allele of rs3025039, rs3212986, and rs712 polymorphisms increases the risk of CRC in the East Asian population, and heterozygote model of rs731236 polymorphism shows protective effect in the Middle East population.
|
31637880 |
2019 |
|
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.
|
23209813 |
2012 |
|
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In genetic polymorphisms analysis, we found that the KRAS rs1137188 variant AA genotype had higher portion of tumor size (≥ 5 cm) (P = 0.01; Bonferroni-adjusted P = 0.04), which suggested that the rs1137188 variant AA genotype may significantly be associated with increased progression of CRC.
|
28328959 |
2017 |
|
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this case-control study of 371 CRC cases and 246 healthy controls, we analyzed the association between one SNP (rs1137188G > A) in the KRAS gene and four SNPs (rs3025039C > T, rs3025040C > T, rs3025053G > A and rs10434A > G) in the VEGF gene and CRC susceptibility by the improved multiplex ligase detection reaction (iMLDR) method.
|
28328959 |
2017 |
|
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer.
|
22753589 |
2012 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |